['breast cancer']
['utd1 injection plus capecitabine', 'capecitabine']

        Inclusion Criteria:

          1. Histologically and/or cytologically diagnosed patients with advanced, metastatic
             breast cancer,or lacking standard therapy or being failed to or recurrent after
             standard therapy;

          2. Patients who have previously treated with ≤4 chemotherapeutic regimes;

          3. Patients who have previously treated with an anthracyclin antibiotics and a taxane;

          4. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy of 3 months or
             more;

          5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks
             prior to enrollment;

          6. Neuropathy <CTC2 degree （NCI CTC4.03）within 4 weeks prior to enrollment;

          7. Basically normal results from routine blood test within 1 week prior to enrollment;

          8. Basically normal liver and renal functions within 1 week prior to enrollment;

          9. No abnormal function for major internal organs, no heart diseases.

        Exclusion Criteria:

          1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted
             drugs 4 weeks prior to enrollment, or received other chemotherapies while
             participating in this trial;

          2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous
             taxane treatment related SAE;

          3. Patients of pregnancy or breast feeding;

          4. Patients with previous standard capecitabine treatment ineffective, or patients
             received standard capecitabine treatment effective, but with less than 6 months of
             capecitabine clearance period;

          5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent
             surgery or local radiotherapy, or other emergency treatment;

          6. Patients combined with severe and /or uncontrolled medical conditions, including
             severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe
             infection, severe gastrointestinal ulceration, and patients with incontrollable
             psychiatric history;

          7. Patients with poor compliance;

          8. Patients not fitted for this study determined by the investigators.
      